Cingulate Inc., a pioneering biopharmaceutical company, has recently announced a significant milestone in its journey towards obtaining marketing approval for its lead ADHD asset, CTx-1301. The company has received a $4.3 million waiver from the FDA, underlining its commitment to advancing precision medicine for patients with Attention Deficit Hyperactivity Disorder (ADHD). This waiver, granted through the small business provision of the FD&C Act, will bolster Cingulate’s financial position as it gears up to submit its New Drug Application (NDA) by the end of this month. The CEO, Shane J. Schaffer, expressed enthusiasm about this development, emphasizing the positive impact it will have on the company’s future prospects. Leveraging its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology, Cingulate is poised to revolutionize treatment regimens for ADHD and other prevalent conditions, with a focus on enhancing patient outcomes and quality of life. As Cingulate prepares to commercialize CTx-1301, the company’s dedication to innovation and patient-centric healthcare is evident, positioning it as a key player in the biopharmaceutical landscape.
Read more from manilatimes.net